Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $173.07.

A number of research firms have weighed in on JAZZ. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price objective on the stock. Robert W. Baird cut their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Morgan Stanley lowered their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the period. LSV Asset Management increased its position in Jazz Pharmaceuticals by 4.2% in the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock worth $264,750,000 after buying an additional 99,705 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after buying an additional 527,187 shares during the period. Polaris Capital Management LLC lifted its position in shares of Jazz Pharmaceuticals by 13.0% during the 1st quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock valued at $172,521,000 after buying an additional 165,200 shares during the last quarter. Finally, Capital World Investors bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth $171,943,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $108.64 on Friday. The business’s fifty day moving average is $109.72 and its 200 day moving average is $112.50. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $143.32. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The stock has a market cap of $6.85 billion, a P/E ratio of 22.40, a P/E/G ratio of 1.45 and a beta of 0.58.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.